Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-916, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Tucson, Arizona • Irvine, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cardiomyopathies, Primary
Interventions
(18F)Flutemetamol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced May 21, 2026, 11:07 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced May 21, 2026, 11:07 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Acquired Factor X Deficiency
Interventions
Coagadex(R)
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Carpal Tunnel Syndrome, Amyloidosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced May 21, 2026, 11:07 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Amyloid Cardiomyopathy
Interventions
AG10
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced May 21, 2026, 11:07 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Primary Amyloidosis
Interventions
Cyclophosphamide, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Duarte, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced May 21, 2026, 11:07 PM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
Interventions
IRX4204, Placebo
Drug · Other
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced May 21, 2026, 11:07 PM EDT
Terminated Phase 4 Interventional
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Transthyretin-associated Amyloidosis With Polyneuropathy
Interventions
Fx-1006A
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced May 21, 2026, 11:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Decline
Interventions
[18F]AV-1451, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Neil M Rofsky, MD, MHA
Other
Eligibility
38 Years to 96 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced May 21, 2026, 11:07 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Asymptomatic Amyloid-positive
Interventions
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced May 21, 2026, 11:07 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Transthyretin Gene Mutation
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 80 Years
Enrollment
500 participants
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced May 21, 2026, 11:07 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Interventions
Inotersen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced May 21, 2026, 11:07 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Naples, Florida • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glendale, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced May 21, 2026, 11:07 PM EDT